X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19

Content Team by Content Team
7th April 2020
in News
GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19

Golfers Against Cancer takes pride in identifying research projects dedicated to specific work targeting various forms of cancer. One such area the organization has supported involves immunotherapy. According to the Cancer Research Institute, it is defined as a form of treatment that uses the power of the body’s own immune system to prevent, control and eliminate cancer.

One of GAC’s beneficiaries – Houston Methodist Hospital — is involved in a number of cancer research efforts utilizing immunotherapy. GAC is proud to help fund some of these projects. Now Houston Methodist is looking at a form of immunotherapy in hopes of curbing the effects of COVID-19. They were the first hospital in the nation to try the experimental therapy which involves a transfusion of blood from a patient who has recovered from COVID-19 into a critically ill patient.

The treatment has been fast-tracked as the death toll from the pandemic continues to rise. The Food and Drug Administration approved Methodist’s “emergency investigational new drug” application to test the therapy.

Plasma from someone who has recovered from COVID-19 contains antibodies made by the immune system to attack the virus. The hope is that transfusing such plasma into a patient still fighting the virus may transfer the power of the antibodies into a healing, possibly life-saving therapy.

GAC Founder and Co-Chair Bobby Jones said there are a number of organizations helping in this cause. In addition to Houston Methodist, MD Anderson is another GAC beneficiary that is a leader in seeking solutions to critical diseases. Their own Dr. Jim Allison, who was GAC’s Person of the Year in 2018, won the Nobel Prize for his work in immunology. And we’re also proud that our GAC Dinners for Cancer Research in New York City and Boston have supported similar work at institutions in those areas.

Though it is too early to know if the therapy is benefiting patients, medical scientists remain hopeful.

Dan McIntyre, who is the GAC Co-Chair along with Jones, says “I think I speak for all of the board members, sponsors and volunteers of our organization when I say that we couldn’t be more pleased that the dollars we raise provide so much value to medical research. And sometimes therapies targeting cancer may, in one form or another, help in curing other diseases like the one our nation is faced with today.”

Previous Post

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

Next Post

Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In